Navigation Links
Mach One Corporation Files its Form SB-2 with the SEC
Date:10/16/2007

LAS VEGAS, Oct. 16 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN) is proud to announce that it has filed its SB-2 registration with the Securities and Exchange Commission. The company had announced previously its intention of becoming a fully reporting company under the 1934 Act, and today made it official. The company is next filing to be listed on the OTCBB following the effectiveness of the SB-2. "This is a monumental day for Mach One; we are now poised to move forward as fully reporting company with the next step -- the OTCBB," said Monte Tobin, CEO of Mach One. "Upon the effectiveness of the registration, we will make a public announcement for the benefit of our shareholders and future shareholders.

Mach One Corporation is currently trading on the Pink Sheets, under the symbol MNCN. Upon the effective date of the filing, the Company will attain Section 12 (g) reporting status with the SEC, under the Exchange Act of 1934, which will allow for broader market participation in the Company's shares by institutional investors. As a reporting company, Mach One Corporation will be required to file annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, and reports of unusual events on Form 8K. In addition, the Company will be required to solicit proxies for its annual meetings in accordance to Section 14 of the Securities Exchange Act of 1934 and other reporting requirements will apply to management shareholdings.

Investors can view the filing by accessing the SEC's website at http://www.sec.gov.

About Mach One Corporation

The company (http://www.machonecorp.com) specializes in Immune or Gamma Globulin replacement (IgG) for the equine and bovine markets. Through it's subsidiary company VDx, Inc., the company plans full scale manufacturing and distribution of Immunogam(TM), a colostrums replacement, supplement and prophylactic, in sterile powder form, that can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market along with an added ingredient for the elimination of Mastitis and Johnnes disease.

Cautionary Statement: This news release may include certain "Forward- looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Novartis files application with FDA for Zometa
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
5. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
6. Personality profiles of gamblers and substance abusers are similar
7. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
8. Venus Remedies Files 5th International Patent Application
9. Shoaib Akhtar files appeal against ban
10. AIIMS Official Files Complaint Against Venugopal
11. Glaxo Files Cancer Drug For Approval With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... GA (PRWEB) , ... January 16, 2017 , ... ... to announce their recent partnership with an innovator in the wheelchair accessibility industry, ... to motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new ...
(Date:1/16/2017)... ... ... One thing common to all types of cancer is that it’s a ... money spent screening for and treating cancer in the United States is estimated to ... than in any other country that has an advanced healthcare system, sometimes spending as ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
(Date:1/15/2017)... ... 14, 2017 , ... Wondering where to go this Valentine's Day? Well, there ... for a romantic, lobster feast in the comfort of your own home. Lobster Gram ... dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and services ... Scale is now available on Apple as a fun, free emoji sticker pack for ... one of the ten color coded values on The Emoji Scale. , On ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Vital Signs Monitoring Devices Market ... Forecast, 2014-2022", projects that the global vital signs monitoring devices ... expected to reach $5,491 million by 2022, growing at a ... America was the leading regional market in global ...
(Date:1/16/2017)... Oregon and PUNE, India , January 16, 2017 ... Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry Forecast, ... is expected to reach $4,531 million by 2022, registering a CAGR of 6.42% ... for more than one-third share of the global volume in 2015. ... ...
(Date:1/16/2017)... 16, 2017  Dovetail Genomics today announced the commercial ... service, which yields chromosome-scale genome assemblies. The service is ... workshop on Jan. 17 at the Plant & Animal ... . "We are thrilled to be ... our Dovetail Hi-C offering," said Todd Dickinson , ...
Breaking Medicine Technology: